Xilia-Trio 2 Tablet SR is a combination oral antidiabetic medication containing Glimepiride (2mg), Metformin (500mg), and Voglibose (0.2mg), formulated to improve glycemic control in patients with type 2 diabetes mellitus. Glimepiride, a sulfonylurea, stimulates pancreatic beta cells to increase insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and enhances peripheral insulin sensitivity, contributing to improved glucose uptake and utilization. Voglibose, an alpha-glucosidase inhibitor, delays carbohydrate absorption in the intestines, reducing postprandial hyperglycemia. The sustained-release formulation ensures gradual drug release, promoting stable plasma concentrations and improved patient compliance. Xilia-Trio 2 is indicated for patients inadequately controlled on diet and exercise alone or those requiring combination therapy to achieve optimal glycemic targets. It is essential to monitor blood glucose levels regularly and adjust dosage based on therapeutic response and tolerability. Contraindications include type 1 diabetes, diabetic ketoacidosis, severe renal or hepatic impairment, and hypersensitivity to any component. Common adverse effects may include gastrointestinal disturbances, hypoglycemia, and rarely, lactic acidosis. This medication should be used under medical supervision with appropriate lifestyle modifications to maximize efficacy and minimize risks.